Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer

Purpose: The complete molecular basis of the organ-specificity of metastasis is elusive. This study aimed to provide an independent characterization of the transcriptional landscape of breast cancer metastases with the specific objective to identify liver metastasis–selective genes of prognostic importance following primary tumor diagnosis. Experimental Design: A cohort of 304 women with advanced breast cancer was studied. Associations between the site of recurrence and clinicopathologic features were investigated. Fine-needle aspirates of metastases (n = 91) were subjected to whole-genome transcriptional profiling. Liver metastasis–selective genes were identified by significance analysis of microarray (SAM) analyses and independently validated in external datasets. Finally, the prognostic relevance of the liver metastasis–selective genes in primary breast cancer was tested. Results: Liver relapse was associated with estrogen receptor (ER) expression (P = 0.002), luminal B subtype (P = 0.01), and was prognostic for an inferior postrelapse survival (P = 0.01). The major variation in the transcriptional landscape of metastases was also associated with ER expression and molecular subtype. However, liver metastases displayed unique transcriptional fingerprints, characterized by downregulation of extracellular matrix (i.e., stromal) genes. Importantly, we identified a 17-gene liver metastasis–selective signature, which was significantly and independently prognostic for shorter relapse-free (P < 0.001) and overall (P = 0.001) survival in ER-positive tumors. Remarkably, this signature remained independently prognostic for shorter relapse-free survival (P = 0.001) among luminal A tumors. Conclusions: Extracellular matrix (stromal) genes can be used to partition breast cancer by site of relapse and may be used to further refine prognostication in ER positive primary breast cancer. Clin Cancer Res; 22(1); 146–57. ©2015 AACR.

[1]  Marc E. Lenburg,et al.  Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity , 2014, PloS one.

[2]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[3]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[4]  M. Fernö,et al.  Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial , 2012, Breast Cancer Research and Treatment.

[5]  Eytan Domany,et al.  Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles , 2007, Proceedings of the National Academy of Sciences.

[6]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[7]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[10]  D. Yardley.  Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. , 2010, Clinical breast cancer.

[11]  N. Pavlidis,et al.  Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women , 2006, Breast Cancer Research and Treatment.

[12]  Larry Norton,et al.  Latent bone metastasis in breast cancer tied to Src-dependent survival signals. , 2009, Cancer cell.

[13]  Jean-Marc Guinebretière,et al.  A six-gene signature predicting breast cancer lung metastasis. , 2008, Cancer research.

[14]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[15]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[16]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[17]  Annuska M Glas,et al.  Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  K. Gelmon,et al.  Patterns of relapse in breast cancer: changes over time , 2010, Breast Cancer Research and Treatment.

[20]  Mårten Fernö,et al.  Claudin‐2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences , 2014, Molecular oncology.

[21]  F. Pépin,et al.  Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes , 2011, Oncogene.

[22]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Namer,et al.  Prognostic factors in 1,038 women with metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[25]  J. Foekens,et al.  Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma , 2013, Cell.

[26]  Melania Pintilie,et al.  Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: An aCGH study , 2009, Genes, chromosomes & cancer.

[27]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[28]  Z. Dong,et al.  Claudin-2 Promotes Breast Cancer Liver Metastasis by Facilitating Tumor Cell Interactions with Hepatocytes , 2012, Molecular and Cellular Biology.

[29]  M. Ringnér,et al.  The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition , 2012, Breast Cancer Research.

[30]  T. Sørlie,et al.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.

[31]  M. Dunning,et al.  Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.

[32]  W. Liang,et al.  9) TM4 Microarray Software Suite , 2006 .

[33]  Lori Shepherd,et al.  Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach , 2011, Journal of Cancer Research and Clinical Oncology.

[34]  M. Piccart,et al.  Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. , 2003, European journal of cancer.

[35]  I. Fidler,et al.  AACR centennial series: the biology of cancer metastasis: historical perspective. , 2010, Cancer research.

[36]  H. Aburatani,et al.  Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. , 2005, Genomics.

[37]  M. Nieto,et al.  Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. , 2012, Cancer cell.

[38]  Johan Staaf,et al.  GOBO: Gene Expression-Based Outcome for Breast Cancer Online , 2011, PloS one.

[39]  Charles M. Perou,et al.  Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse , 2011, Breast Cancer Research and Treatment.

[40]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[41]  T. Bates,et al.  The significance of the site of recurrence to subsequent breast cancer survival. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[42]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  R. Gelber,et al.  Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.